Cargando…

Loss of the Wild-type KRAS Allele Promotes Pancreatic Cancer Progression through Functional Activation of YAP1

Human pancreatic ductal adenocarcinoma (PDAC) harboring one KRAS mutant allele often displays increasing genomic loss of the remaining wild-type (WT) allele (known as LOH at KRAS) as tumors progress to metastasis, yet the molecular ramification of this WT allelic loss is unknown. In this study, we s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Han, Yu, Chih-Chieh, Fine, Stuart A., Youssof, Ayman Lee, Yang, Ye-Ran, Yan, Jun, Karg, Dillon C., Cheung, Edwin C., Friedman, Richard A., Ying, Haoqiang, Chen, Emily I., Luo, Ji, Miao, Yi, Qiu, Wanglong, Su, Gloria H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688281/ https://www.ncbi.nlm.nih.gov/pubmed/34663879 http://dx.doi.org/10.1038/s41388-021-02040-9

Ejemplares similares

Smad4 Loss Synergizes with TGFα Overexpression in Promoting Pancreatic Metaplasia, PanIN Development, and Fibrosis
por: Garcia-Carracedo, Dario, et al.
Publicado: (2015)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in KRAS Wild-Type Patients
por: Er, Tze-Kiong, et al.
Publicado: (2014)

The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer
por: Wu, De-Wei, et al.
Publicado: (2017)

The origins and genetic interactions of KRAS mutations are allele- and tissue-specific
por: Cook, Joshua H., et al.
Publicado: (2021)

Role and regulation of Yap in KrasG12D-induced lung cancer
por: Mao, Yaopan, et al.
Publicado: (2017)

Initiation of human mammary cell tumorigenesis by mutant KRAS requires YAP inactivation
por: Lefort, Sylvain, et al.
Publicado: (2019)

MICA (∗)012:01 Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer
por: Ding, Weifeng, et al.
Publicado: (2020)

Biological significance of KRAS mutant allele expression in ovarian endometriosis
por: Yachida, Nozomi, et al.
Publicado: (2021)

Alisertib exerts KRAS allele‑specific anticancer effects on colorectal cancer cell lines
por: Ren, Baojun, et al.
Publicado: (2023)

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex
por: Rao, Donald D., et al.
Publicado: (2018)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines
por: Ulmer, Bastian, et al.
Publicado: (2022)

Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling
por: Zhang, Baoyuan, et al.
Publicado: (2021)

Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy
por: Alves, Sara, et al.
Publicado: (2015)

Fbxw7 Deletion Accelerates Kras(G12D)-Driven Pancreatic Tumorigenesis via Yap Accumulation()()()
por: Zhang, Qiang, et al.
Publicado: (2016)

Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma
por: Mohamed, Abdalla D., et al.
Publicado: (2018)

Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance
por: Rozengurt, Enrique, et al.
Publicado: (2021)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
por: Geredeli, Caglayan, et al.
Publicado: (2018)

Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR
por: Orue, Andrea, et al.
Publicado: (2016)

Allele-Specific PCR for KRAS Mutation Detection Using Phosphoryl Guanidine Modified Primers
por: Chubarov, Alexey S., et al.
Publicado: (2020)

KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer
por: Suzuki, Tatsunori, et al.
Publicado: (2022)

MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells
por: Xu, Huanji, et al.
Publicado: (2019)

Allelic Expression Imbalance Analysis Identified YAP1 Amplification in p53- Dependent Osteosarcoma
por: Niu, Guanglin, et al.
Publicado: (2021)

Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS
por: Luo, Shuna, et al.
Publicado: (2020)

Disruption of p16 and Activation of Kras in Pancreas Increase Ductal Adenocarcinoma Formation and Metastasis in vivo
por: Qiu, Wanglong, et al.
Publicado: (2011)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
por: Guedes, Joana G, et al.
Publicado: (2013)

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
por: Naseem, Madiha, et al.
Publicado: (2021)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Adaptive Gene Content and Allele Distribution Variations in the Wild and Domesticated Populations of Saccharomyces cerevisiae
por: Han, Da-Yong, et al.
Publicado: (2021)

Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma
por: Alhenc-Gelas, Marion, et al.
Publicado: (2019)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice
por: Sundström, Magnus, et al.
Publicado: (2010)

Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells
por: Lee, Wookjae, et al.
Publicado: (2018)

Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1
por: Kandasamy, Palanivel, et al.
Publicado: (2021)

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
por: Hagenbeek, Thijs J., et al.
Publicado: (2023)

Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
por: Santana-Codina, Naiara, et al.
Publicado: (2018)

KRAS K104 modification affects the KRAS(G12D)-GEF interaction and mediates cell growth and motility
por: Chen, Chih-Chieh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dv2m0j17fg3e27vinnc1ucqmpn